Literature DB >> 81964

Tamoxifen and thrombosis.

K Nevasaari, M Heikkinen, P J Taskinen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 81964     DOI： 10.1016/s0140-6736(78)91668-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  14 in total

Review 1.  Approach to chemotherapy-associated thrombosis.

Authors:  Peter Oppelt; Anthony Betbadal; Lalitha Nayak
Journal:  Vasc Med       Date:  2015-04       Impact factor: 3.239

2.  Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels.

Authors:  G Bertelli; P Pronzato; D Amoroso; M P Cusimano; P F Conte; G Montagna; S Bertolini; R Rosso
Journal:  Breast Cancer Res Treat       Date:  1988-12       Impact factor: 4.872

Review 3.  Hormone resistance, invasiveness, and metastatic potential in breast cancer.

Authors:  R Clarke; E W Thompson; F Leonessa; J Lippman; M McGarvey; T L Frandsen; N Brünner
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

Review 4.  Antiestrogens--tamoxifen, SERMs and beyond.

Authors:  K Dhingra
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 5.  Clinical pharmacology of selective estrogen receptor modulators.

Authors:  B Haynes; M Dowsett
Journal:  Drugs Aging       Date:  1999-05       Impact factor: 3.923

Review 6.  Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

Review 7.  Tamoxifen as adjuvant therapy in breast cancer. Current status.

Authors:  P N Plowman
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

Review 8.  Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer.

Authors:  V C Jordan
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

9.  Tamoxifen and risk of idiopathic venous thromboembolism.

Authors:  C R Meier; H Jick
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

Review 10.  A risk-benefit assessment of tamoxifen therapy.

Authors:  W H Catherino; V C Jordan
Journal:  Drug Saf       Date:  1993-05       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.